TOKYO, Sept. 1, 2014 /PRNewswire/ -- Daiichi Sankyo
Company, Limited (Tokyo Stock Exchange: 4568; hereafter Daiichi
Sankyo) announced on September 1
details of the application for its Take a New Challenge for Drug
Discovery (TaNeDS) Global Programme 2014, a collaborative drug
discovery initiative for universities and research institutes in
Europe.
The TaNeDS program was launched in Japan in 2011 to help discover new lines of
research through open innovation. From 2013, it expanded abroad,
opening up to researchers in Germany, Switzerland and Austria, and becoming known as the TaNeDS
Global Program. Now, in 2014, it has expanded further across
Europe to include all EU member
countries. The program is conducted with the aim of realizing
Daiichi Sankyo's corporate slogan of "Passion for Innovation.
Compassion for Patients.(TM)" through increasing collaborative
opportunities with researchers in Europe. U3 Pharma GmbH (headquarters:
Munich, Germany; hereafter, U3
Pharma), a wholly owned subsidiary of Daiichi Sankyo, is also
participating in the program in order to nurture the seeds of drug
discovery for the next generation.
About the TaNeDS Global Programme 2014
(1) Countries where research could be conducted:
All EU member countries plus Norway and Switzerland.
(2) Overview of research programs
Daiichi Sankyo seeks innovative technological research
collaborators for novel drug discovery and testing projects that
could result in novel drug discovery and novel new drugs.
(3) Research themes
1. Cancer
New targeted and investigative research for small-molecule and
biologic treatments (antibody drugs, etc.).
2. Cardiovascular and metabolic disorders
New mechanisms and drug treatments for obesity, kidney and
renovascular- related disorders.
3. Other disorders
New mechanisms and drug treatments for genetic disorders, new
drug treatments for pain, genetic analysis and new drug research
for rare diseases.
4. Revolutionary drug discovery technology
New biologic technology, target molecules and delivery systems
for nucleic acid treatments, new technology for drug development
based on protein structural analysis.
For more details, please visit the TaNeDS Global Programme page
at: http://www.daiichisankyo.com/rd/taneds/index.html
(4) Budget and period of research
Up to 150,000 euros per year for
collaborative research projects lasting up to 2 years.
(5) Eligibility
Researchers of any nationality employed by universities,
research institutes and start-up companies within the EU, as well
as Norway and Switzerland, who can conduct research in those
countries on projects that match Daiichi Sankyo's desired research
themes.
(6) Selection process
Daiichi Sankyo and U3 Pharma researchers will select research
projects that match their research needs as well as demonstrate
originality, potential and promise as drug discovery
candidates.
(7) Schedule
Application period: October 1 to November
15, 2014
First shortlist selection period: Mid-November to mid-December 2014
Second shortlist selection period: Mid-December 2014 to early February 2015
Start of research programs: From mid-April
2015
Selection Results for the TaNeDS Global Program 2013
The application process for 2013 resulted in 2 projects being
selected and those collaborations are currently underway.
(1) Applications 49
(2) Selected 2
The two selected laboratories, from the University of Wuertzburg
in Germany and the Medical
University of Innsbruck in Austria, are both conducting research in the
field of cancer therapy.
About Daiichi Sankyo Company, Limited
Representative: Joji Nakayama,
Representative Director, President and CEO
(Code No.: 4568, First Section, Tokyo Stock Exchange)
Contact:
Toshiya Kondo
Senior Director, Public Relations Group
Corporate Communications Department
Daiichi Sankyo Company, Limited
Tel: +81-3-6225-1126
kondo.toshiya.cj@daiichisankyo.co.jp
http://www.daiichisankyo.com